Developing Next Generation Gene Therapies

Splice Bio is a biotech company based on intein technologies developed in the Muir Lab at Princeton University. We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.

Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors

BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs) aimed at treating people suffering from cystic fibrosis (CF). The Company will receive up to $343,000 in research funding to advance its proprietary 3^rd-generation intein platform and develop novel AAVs better suited to target specific cells in the lungs of people with CF.

Read the Press Release

ProteoDesign announces new investment led by YSIOS Capital and rebrands as Splice Bio

ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology.
This pioneering platform has the potential to target genetic diseases that cannot be addressed with current gene therapies.
Ysios and Asabys join the board of directors as new investors

BARCELONA, September 15, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partners from its fund Sabadell Asabys. This financing round was organized thanks to the support of existing shareholder Caixa Capital Risc. ProteoDesign is rebranding as Splice Bio to reflect on its progress with its proprietary intein platform, based on pioneering research by the company’s co-founders, and its new focus on gene therapy.

Read the Press Release